Energetic dissection of Gleevec's selectivity toward human tyrosine kinases

Nature Structural and Molecular Biology

Volumn 21, Issue 10, 2014, Pages 848-853

  Agafonov, Roman V ^a   Wilson, Christopher ^a   Otten, Renee ^a   Buosi, Vanessa ^a   Kern, Dorothee ^a  

^a BRANDEIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE; ABELSON KINASE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ARTICLE; BINDING KINETICS; CONFORMATIONAL TRANSITION; DISSOCIATION; DRUG BINDING; DRUG SELECTIVITY; ENERGY; ENZYME ACTIVE SITE; ENZYME BINDING; KINETICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PLASTICITY; PRIORITY JOURNAL; STEADY STATE; TITRIMETRY; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; ENZYMOLOGY; HUMAN; NEOPLASM; PROTEIN TERTIARY STRUCTURE; THERMODYNAMICS; ULTRASTRUCTURE;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL LINE; HUMANS; IMATINIB MESYLATE; KINETICS; NEOPLASMS; PIPERAZINES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; SRC-FAMILY KINASES; THERMODYNAMICS;

EID: 84923367313     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.2891     Document Type: Article

References (35)

1. Jura, N. et al. Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol. Cell 42, 9-22 (2011).
2. Kornev, A.P., Taylor, S.S. Defining the conserved internal architecture of a protein kinase. Biochim. Biophys. Acta 1804, 440-444 (2010).
3. Taylor, S.S., Keshwani, M.M., Steichen, J.M., Kornev, A.P. Evolution of the eukaryotic protein kinases as dynamic molecular switches. Phil. Trans. R. Soc. Lond. B 367, 2517-2528 (2012).
4. Hunter, T. Tyrosine phosphorylation: thirty years and counting. Curr. Opin. Cell Biol. 21, 140-146 (2009).
5. Cohen, P. Protein kinases: the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1, 309-315 (2002).
6. Huse, M., Kuriyan, J. The conformational plasticity of protein kinases. Cell 109, 275-282 (2002).
7. Nagar, B. c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571). J. Nutr. 137, 1518S-1523S (2007).
8. Harrison, S.C. Variation on an Src-like theme. Cell 112, 737-740 (2003).
9. Azam, M. et al. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc. Natl. Acad. Sci. USA 103, 9244-9249 (2006).
10. Winter, G.E. et al. Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nat. Chem. Biol. 8, 905-912 (2012).
11. Dar, A.C., Shokat, K.M. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu. Rev. Biochem. 80, 769-795 (2011).
12. Seeliger, M.A. et al. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure 15, 299-311 (2007).
13. Nagar, B. et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236-4243 (2002).
14. Schindler, T. et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938-1942 (2000).
15. Williams, J.C. et al. The 2.35 A crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions. J. Mol. Biol. 274, 757-775 (1997).
16. Xu, W., Doshi, A., Lei, M., Eck, M.J., Harrison, S.C. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cell 3, 629-638 (1999).
17. Xu, W., Harrison, S.C., Eck, M.J. Three-dimensional structure of the tyrosine kinase c-Src. Nature 385, 595-602 (1997).
18. Levinson, N.M. et al. A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol. 4, e144 (2006).
19. Aleksandrov, A., Simonson, T. Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases. J. Biol. Chem. 285, 13807-13815 (2010).
20. Lin, Y.L., Meng, Y., Jiang, W., Roux, B. Explaining why Gleevec is a specific and potent inhibitor of Abl kinase. Proc. Natl. Acad. Sci. USA 110, 1664-1669 (2013).
21. Lovera, S. et al. The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation. J. Am. Chem. Soc. 134, 2496-2499 (2012).
22. Cowan-Jacob, S.W. et al. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 13, 861-871 (2005).
23. Dar, A.C., Lopez, M.S., Shokat, K.M. Small molecule recognition of c-Src via the Imatinib-binding conformation. Chem. Biol. 15, 1015-1022 (2008).
24. Vajpai, N. et al. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J. Biol. Chem. 283, 18292-18302 (2008).
25. Vogtherr, M. et al. NMR characterization of kinase p38 dynamics in free and ligand-bound forms. Angew. Chem. Int. Edn. Engl. 45, 993-997 (2006).
26. Shan, Y. et al. A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc. Natl. Acad. Sci. USA 106, 139-144 (2009).
27. Kovrigin, E.L. NMR line shapes and multi-state binding equilibria. J. Biomol. NMR 53, 257-270 (2012).
28. Johnson, K.A. Fitting enzyme kinetic data with KinTek Global Kinetic Explorer. Methods Enzymol. 467, 601-626 (2009).
29. Campos-Olivas, R., Marenchino, M., Scapozza, L., Gervasio, F.L. Backbone assignment of the tyrosine kinase Src catalytic domain in complex with imatinib. Biomol. NMR Assign. 5, 221-224 (2011).
30. Skora, L., Mestan, J., Fabbro, D., Jahnke, W., Grzesiek, S. NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors. Proc. Natl. Acad. Sci. USA 110, E4437-E4445 (2013).
31. Nagar, B. et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859-871 (2003).
32. Johnson, K.A., Simpson, Z.B., Blom, T. FitSpace explorer: an algorithm to evaluate multidimensional parameter space in fitting kinetic data. Anal. Biochem. 387, 30-41 (2009).
33. Ericsson, U.B., Hallberg, B.M., Detitta, G.T., Dekker, N., Nordlund, P. Thermofluor-based high-throughput stability optimization of proteins for structural studies. Anal. Biochem. 357, 289-298 (2006).
34. Delaglio, F. et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277-293 (1995).
35. Vranken, W.F. et al. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 59, 687-696 (2005).